Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ACCESS Act back in House (and Senate)

Executive Summary

Sen. Sam Brownback, R-Kan., and Rep. Diane Watson, D-Calif., re-introduced the Access, Compassion, Care and Ethics for Seriously Ill Patients Act (ACCESS) May 21. The bill, initially introduced in 2005, would expand investigational treatment access for terminally ill patients who have exhausted other medical options (1"The Pink Sheet," Aug. 27, 2007, p. 9)

You may also be interested in...



Abigail Alliance Looks For Paths Forward After Court Blocks Drug Access Suit

After losing at the appeals court in its bid to overturn FDA's regulations on access to experimental therapies, the Abigail Alliance is considering several legal options. The group is preparing to ask the Supreme Court to consider the case, but if that bid fails, alternatives include congressional action and bringing another case in a different jurisdiction

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.

UsernamePublicRestriction

Register

OM009724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel